ArticleFrontiers in psychiatry2025
Plasma exosomal miR-30b-5p attenuates neuroinflammation in a rat model of autism spectrum disorder.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dysregulation of miRNAs in Sicilian Patients with Autism Spectrum Disorder.Biomedicines · 2026Article
- Neuroinflammatory mechanisms and pharmacological advances in autism spectrum disorder: from inflammatory pathways to targeted interventions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is growing evidence that exosomes play an important role in the pathogenesis of central nervous system diseases, but little is known about the relationship between exosomes and autism spectrum disorder (ASD). Methods: In this study, a rat model of ASD was generated via prenatal exposure to valproic acid (VPA). Three-chamber social interaction, self-grooming and marble burying tests were utilized for behavioral assessment. The plasma exosomal microRNA (miRNA) expression profiles of VPA-treated rats and sham rats were analyzed. Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and IL-1β levels were measured by ELISA. miR-30b-5p in the brains was assessed by qRT-PCR. Epidermal growth factor receptor (EGFR), p-p38/p38, and CaMKII were assessed by Western blot. In addition, the regulation of miR-30b-5p/EGFR was examined by lateral ventricle injection with miR-30b-5p agomir in VPA-exposed rats. Results: VPA-exposed rats exhibited ASD-like behaviors. The level of miR-30b-5p was significantly lower in the plasma exosomes and brains of VPA-exposed rats than in those of sham rats. In addition, the levels of inflammatory factors, EGFR, p-p38/p38, and CaMKII were increased in the brains of VPA-exposed rats. Moreover, overexpressing miR-30b-5p ameliorated ASD-like behaviors and decreased the expression of inflammatory factors, EGFR, p-p38/p38, and CaMKII in the brains of VPA-exposed rats. Conclusions: Our study highlights that plasma exosomal miR-30b-5p attenuates neuroinflammation in a rat model of ASD by modulating EGFR through the MAPK signaling pathway and calcium signaling pathway. This study provides novel perspectives on plasma exosomal miR-30b-5p, which could be considered a potential therapeutic target for the treatment of ASD in the clinic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.